Abiopharma

U.S. Global Investors Announces Intent to Restate EPS for the March 31, 2026, Financial Statements; Underlying Financial Results Unchanged

Clinical trial NCT06619860 updates: 1. completion date: 2026-05-30 → 2027-04-22 2. primary completion date: 2026-04-30 → 2027-03-25

Clinical trial NCT07325461 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT07555483 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-04-21 → 2026-05-05 3. completion date: 2026-09-29 → 2027-09-30 4. primary completion date: 2026-09-29 → 2027-09-30

Clinical trial NCT07459751: status: ENROLLING_BY_INVITATION → RECRUITING.

Clinical trial NCT06052631: start date: 2026-06-03 → 2026-06-04.

Clinical trial NCT04287647 updates: 1. status: RECRUITING → TERMINATED 2. completion date: 2026-06-06 → 2026-05-27 3. primary completion date: 2026-06-06 → 2026-05-27 4. enrollment: 36 → 8 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT07020936 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. completion date: 2026-03-30 → 2026-10-31 3. primary completion date: 2026-03-30 → 2026-10-31 4. enrollment: 36 → 42 participants

Clinical trial NCT07419373 updates: 1. status: RECRUITING → ACTIVE_NOT_RECRUITING 2. start date: 2026-02-01 → 2026-02-14

Clinical trial NCT07455578 updates: 1. status: NOT_YET_RECRUITING → RECRUITING 2. start date: 2026-02-01 → 2026-06-01 3. completion date: 2027-06-01 → 2027-09-01 4. primary completion date: 2027-06-01 → 2027-09-01